Abaloparatide benefits a wide range of postmenopausal women with osteoporosis

Posted by on September 19, 2016 4:07 pm
Categories: health

A recent analysis of results from a randomized controlled clinical trial indicates that abaloparatide-SC, a novel therapy for osteoporosis, provides consistent protection against bone fractures in postmenopausal women with osteoporosis regardless of their baseline bone density, age, and previous history of fracture.

Leave a Reply

Your email address will not be published. Required fields are marked *